Literature DB >> 15844693

Efficacy and tolerability of rifampicin-based rescue therapy for Helicobacter pylori eradication failure in peptic ulcer disease.

Vineet Ahuja1, Vikram Bhatia, S Dattagupta, Akshay Raizada, Mahesh Prakash Sharma.   

Abstract

In vitro activity of rifampicin has been shown against H. pylori. It has also been reported that the prevalence of H. pylori is low in patients with tuberculosis treated with rifampicin. Clinical trials are required to establish the efficacy of rifampicin as a salvage therapy for eradication of H. pylori. We aimed to evaluate the efficacy of rifampicin-based salvage therapy for eradication of H. pylori in patients with peptic ulcer disease. Twenty-eight patients with peptic ulcer disease who either had failed eradication of H. pylori or had a recurrence of H. pylori following successful eradication were included in the prospective study. The inclusion criteria included one or more failed attempts at eradication and presence of H. pylori infection as evidenced by positivity of at least two of three tests: rapid urease test (RUT), 14C urea breath test (UBT), and histology. The subjects were treated with a 10-day regimen consisting of rifampicin, 450 mg od, tetracycline, 1 g bd, and esomeprazole, 40 mg bd. Four weeks after completion of therapy, H. pylori status was assessed by RUT, 14C, UBT, and histology. Liver function tests were done before and at the end of therapy. The study subjects included 25 males and 3 females with a mean age of 33.7+/-8.92 years (range: 22-65 years). The median duration of symptoms was 42 months, with a range of 1-180 months. The median number of eradication attempts was two, with one prior attempt in 6 (21.4%), two attempts in 19 (67.9%), and three attempts in 3 (10.7%) patients. Successful H. pylori eradication as defined by concomitant negativity of RUT, UBT, and histology with special stains was achieved in 32.1% (9/28) of patients by intention-to-treat and 33.3% (9/27) of patients by per-protocol analysis. This pilot study suggests that rifampicin-based regimes have no role as salvage eradication therapy in refractory cases of H. pylori infection with peptic ulcer disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15844693     DOI: 10.1007/s10620-005-2548-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

1.  Rifampin and rifabutin resistance mechanism in Helicobacter pylori.

Authors:  M Heep; D Beck; E Bayerdörffer; N Lehn
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  High recurrence rate of Helicobacter pylori infection in developing countries.

Authors:  Vineet Ahuja; Mahesh Prakash Sharma
Journal:  Gastroenterology       Date:  2002-08       Impact factor: 22.682

3.  Treatment of antibiotic-resistant Helicobacter pylori.

Authors:  F Perri; V Festa; A Andriulli
Journal:  N Engl J Med       Date:  1998-07-02       Impact factor: 91.245

4.  Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection.

Authors:  W M Wong; Q Gu; S K Lam; F M Y Fung; K C Lai; W H C Hu; Y K Yee; C K Chan; H H X Xia; M F Yuen; B C Y Wong
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

5.  Evaluation of treatment regimens to cure Helicobacter pylori infection--a meta-analysis.

Authors:  R J Laheij; L G Rossum; J B Jansen; H Straatman; A L Verbeek
Journal:  Aliment Pharmacol Ther       Date:  1999-07       Impact factor: 8.171

6.  Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.

Authors:  F Perri; V Festa; R Clemente; M R Villani; M Quitadamo; N Caruso; M L Bergoli; A Andriulli
Journal:  Am J Gastroenterol       Date:  2001-01       Impact factor: 10.864

7.  Evaluation of endoscopy-based diagnostic methods for the detection of Helicobacter pylori.

Authors:  S Saksena; S Dasarathy; K Verma; V Ahuja; M P Sharma
Journal:  Indian J Gastroenterol       Date:  2000 Apr-Jun

8.  In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults.

Authors:  Shigeru Fujimura; Seiichi Kato; Takeshi Kawamura; Akira Watanabe
Journal:  J Antimicrob Chemother       Date:  2002-03       Impact factor: 5.790

9.  Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection?

Authors:  V Ahuja; C S Bal; M P Sharma
Journal:  Clin Nucl Med       Date:  1998-12       Impact factor: 7.794

10.  Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country.

Authors:  V Ahuja; A Dhar; C Bal; M P Sharma
Journal:  Aliment Pharmacol Ther       Date:  1998-06       Impact factor: 8.171

View more
  4 in total

Review 1.  Third-line rescue therapy for Helicobacter pylori infection.

Authors:  Rossella Cianci; Massimo Montalto; Franco Pandolfi; Giovan-Battista Gasbarrini; Giovanni Cammarota
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

2.  Helicobacter pylori infection in India from a western perspective.

Authors:  Selvi Thirumurthi; David Y Graham
Journal:  Indian J Med Res       Date:  2012-10       Impact factor: 2.375

3.  Comparison of efficacy and pharmacoeconomics of two Helicobacter pylori eradication regimens in peptic ulcer disease.

Authors:  Syeda Zaineb Kubra Hussaini; Syeda Zaineb Humaira Hussaini; Ruheena Yasmeen; Bader Unnisa; Aamir Ali Asgar Syed; Md Nematullah Khan; Syed Ibrahim Hassan
Journal:  Perspect Clin Res       Date:  2018 Jan-Mar

4.  Comparison between the two drug regimens of PPI+Amoxicillin+ Rifampicin and PPI+Amoxicillin+ Levofloxacin for the treatment of H. pylori infections resistant to the first line drug regimen among patients referred to Ilam clinics.

Authors:  Ghobad Abangah; Alireza Raughani; Parisa Asadollahi; Khairollah Asadollahi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.